Aims Worldwide observational studies are evidencing discordance between guidelines and
real‐world practice regarding direct oral anticoagulant drug (DOAC) doses. This systematic …

Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC)
laboratory monitoring. The aims of the present review were to evaluate published data on …

Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a
fixed dosing regimen. Despite the potential for relative underdosing due to large distribution …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

The purpose of this paper is to study the genetic polymorphisms of related gene loci
(CYP2C9* 3, VKORC1-1639G> A) based on demographic and clinical factors, and use the …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Introduction Venous thromboembolism (VTE) is a leading cause of morbidity and mortality
globally. The direct oral anticoagulants, including rivaroxaban, are relatively novel …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Purpose To investigate real-world prescribing trends and clinical outcomes based on body
mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This …